CRBU

Caribou Biosciences, Inc. is a clinical-stage biotechnology company headquartered in Berkeley, California, developing off-the-shelf CAR-T cell therapies for the treatment of cancer. The company utilizes its proprietary CRISPR genome editing platform to develop next-generation cell therapies with improved anti-tumor activity and reduced manufacturing complexity. Caribou's lead programs target hematologic malignancies and are designed to be manufactured from healthy donor cells rather than a patient's own cells, potentially enabling faster treatment and lower costs. The company was founded by CRISPR pioneer Dr. Jennifer Doudna and has built significant intellectual property around CRISPR-based cellular therapies.